tradingkey.logo

Ani Pharmaceuticals Announces Results From New Day Clinical Trial Of Iluvien® For Use In Patients With Diabetic Macular Edema (Dme)

ReutersJul 23, 2025 10:54 AM

- ANI Pharmaceuticals Inc ANIP.O:

  • ANI PHARMACEUTICALS ANNOUNCES RESULTS FROM NEW DAY CLINICAL TRIAL OF ILUVIEN® FOR USE IN PATIENTS WITH DIABETIC MACULAR EDEMA (DME)

  • ANI PHARMACEUTICALS INC - PRIMARY ENDPOINT WAS MEAN NUMBER OF SUPPLEMENTAL AFLIBERCEPT INJECTIONS

  • ANI PHARMACEUTICALS INC - ILUVIEN SHOWED NUMERICAL REDUCTION IN INJECTIONS BUT NOT SIGNIFICANT

  • ANI PHARMACEUTICALS INC - SECONDARY ENDPOINT MET WITH MEAN TIME OF 185.4 DAYS IN ILUVIEN ARM

  • ANI PHARMACEUTICALS INC - ILUVIEN WELL TOLERATED WITH CONSISTENT SAFETY PROFILE IN TRIAL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI